Genentech Adds Warnings to Avastin

Genentech Inc. has added warnings about a rare brain condition called reversible posterior leukoencephalopathy syndrome, or RPLS, in patients using its cancer drug Avastin, the Food and Drug Administration said.

The drug’s label also now includes information about seven reports of patients who developed holes inside the nose called septum perforations, the FDA said.

South San Francisco-based Genentech said in March that it was working to include the information about the brain condition on the prescribing label while it reviewed data about the frequency of the syndrome.